5 345

Cited 9 times in

Safety and Efficacy of 8-mg Once-daily vs 4-mg Twice-daily Silodosin in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (SILVER Study): A 12-Week, Double-blind, Randomized, Parallel, Multicenter Study

Authors
 Myung-Soo Choo  ;  Miho Song  ;  Jang Hwan Kim  ;  Kyu-Sung Lee  ;  Joon Chul Kim  ;  Sae Woong Kim  ;  Sang-Kuk Yang  ;  Jeong Gu Lee  ;  Jeong Zoo Lee  ;  Dae Kyung Kim  ;  Won Hee Park  ;  Kyung Do Kim  ;  Yong Gil Na  ;  Dong Deuk Kwon  ;  Jae-Seung Paick 
Citation
 UROLOGY, Vol.83(4) : 875-881, 2014 
Journal Title
 UROLOGY 
ISSN
 0090-4295 
Issue Date
2014
MeSH
Aged ; Double-Blind Method ; Drug Administration Schedule ; Humans ; Indoles/administration & dosage* ; Indoles/therapeutic use ; Lower Urinary Tract Symptoms/drug therapy* ; Male ; Middle Aged ; Prospective Studies ; Prostatic Hyperplasia/drug therapy* ; Republic of Korea ; Surveys and Questionnaires ; Treatment Outcome ; Urination/drug effects ; Urological Agents/administration & dosage* ; Urological Agents/therapeutic use
Abstract
OBJECTIVE: To show the noninferiority of silodosin 8-mg once-daily (QD) to 4-mg twice-daily (BID) in efficacy and safety in patients with lower urinary tract symptoms or benign prostatic hyperplasia in the Korean population. METHODS: A prospective, multicenter, double-blind, randomized, comparative study was conducted. A total of 532 male patients aged ≥50 years with lower urinary tract symptoms or benign prostatic hyperplasia were included. All patients received silodosin QD or BID for 12 weeks. The primary end point was the change from baseline in total International Prostate Symptom Score (IPSS) at 12 weeks. Adverse drug reactions, vital signs, and laboratory tests were recorded. RESULTS: A total of 424 patients were randomized to the silodosin QD or BID groups. These groups were not significantly different in baseline characteristics. The mean total IPSS change in QD group was not inferior to that in BID group (-6.70 and -6.94, respectively; 95% confidence interval, -0.88 to 1.36). The QD and BID groups did not significantly differ in the following: percentages of patients with ≥25% (63.41% and 67.82%, respectively; P = .349) or ≥4-point improvement in total IPSS (65.85% and 69.31%, respectively; P = .457), maximum urinary flow rate improvement ≥30% (47.32% and 40.59%, respectively; P = .172), changes in IPSS voiding subscore (-4.42 ± 4.93 and -4.65 ± 4.77; P = .641), IPSS storage subscore (-2.05 ± 3.07 and -2.52 ± 2.97; P = .117), quality of life (-1.19 ± 1.49 and -1.40 ± 1.42; P = .136), maximum urinary flow rate (3.55 ± 5.93 and 3.74 ± 6.79 mL/s; P = .768), International Continence Society male questionnaire score, Patient Goal Achievement Score, or Treatment Satisfaction Question. The 2 groups had similar frequencies of adverse drug reactions. CONCLUSION: QD administration of silodosin was not inferior to BID in efficacy. The 2 groups had similar adverse drug reaction profiles.
Full Text
http://www.sciencedirect.com/science/article/pii/S009042951301457X
DOI
10.1016/j.urology.2013.11.013
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jang Hwan(김장환) ORCID logo https://orcid.org/0000-0002-9056-7072
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/98398
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse